Summary

TB-500 Forte is a commercial variant of TB-500 (synthetic Thymosin Beta-4) marketed by some research peptide vendors as an enhanced formulation, typically containing 10 mg per vial rather than the standard 2-5 mg. The active ingredient is identical to standard TB-500 (Thymosin Beta-4, fragment LKKTETQ). The 'Forte' designation refers to product concentration and packaging, not a different peptide. All research evidence, mechanism, and safety considerations are the same as for standard TB-500.

Mechanism

The mechanism of action of TB-500 Forte is identical to standard TB-500, as the active ingredient is the same peptide (Thymosin Beta-4, fragment LKKTETQ). Thymosin Beta-4 binds G-actin, promotes cell migration and wound healing, stimulates angiogenesis, and exhibits anti-inflammatory properties through NF-kB pathway inhibition. The 'Forte' designation refers to product concentration/packaging, not a different mechanism. See the TB-500 compound profile for full mechanism details.

Protocols

Protocols for TB-500 Forte are the same as standard TB-500 with adjustments for vial size. Typical research protocol: 2-5 mg per week via subcutaneous injection, divided into 1-2 doses. 10 mg vials are reconstituted in 2-4 mL of bacteriostatic water (2.5-5 mg/mL concentration). Common cycle length: 4-6 weeks. All doses for research reference only - no human consumption or medical use is implied.

TB-500 Forte has the same legal status as standard TB-500 in the UK. Not a controlled substance, not MHRA-approved, sold for research purposes only. The MHRA has taken enforcement action against vendors marketing peptide products for human use. WADA prohibits Thymosin Beta-4 in competitive sport. The 'Forte' designation does not change the legal status.

Vendor notes

TB-500 Forte may be available from some UK research peptide vendors in 10 mg vials. Researchers should request certificates of analysis (HPLC purity, mass spectrometry), verify the product is synthetic Thymosin Beta-4 (sequence LKKTETQ), check vendor reputation via the Peptide Data vendor directory, and be aware that 'Forte' is a marketing term, not a quality standard.

References

  1. Goldstein AL, et al. Thymosin beta4: a new peptide therapeutic for wound repair. Ann N Y Acad Sci. 2012;1269:56-62. doi:10.1111/j.1749-6632.2012.06732.x
  2. Philp D, et al. Thymosin beta4 promotes hair growth in normal rats and mice. PLoS One. 2007;2(10):e1009. doi:10.1371/journal.pone.0001009
  3. Bock-Marquette I, et al. Thymosin beta4 acts through Wnt to restore cardiac function. Mol Ther. 2010;18(8):1431-1432. doi:10.1038/mt.2010.137
  4. Smart N, et al. Thymosin beta4 facilitates epicardial neovascularisation. Mol Ther. 2011;19(7):1314-1321. doi:10.1038/mt.2011.45
  5. Crockford D. Development of thymosin beta4 for treatment of patients with ischemic heart disease. Ann N Y Acad Sci. 2007;1112:315-325. doi:10.1196/annals.1415.020